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The risk of tuberculosis (TB) is variable among individuals with latent Mycobacterium tuberculosis 
infection (LTBI), but validated estimates of personalized risk are lacking. In pooled data from 18 
systematically-identified cohort studies from 20 countries, including 80,468 individuals tested for LTBI, 
5-year cumulative incident TB risk among people with untreated LTBI was 15.6% (95% CI 8.0-29.2) 
among child contacts, 4.8% (3.0-7.7) among adult contacts, 5.0% (1.6-14.5) among migrants, and 
4.8% (1.5-14.3) among immunocompromised groups. We confirmed highly variable estimates within 
risk groups, necessitating an individualized approach to risk-stratification. We thus developed a 
personalised risk predictor for incident TB (PERISKOPE-TB) that combines a quantitative measure of 
T-cell sensitization and clinical covariates. Internal-external cross-validation of the model 
demonstrated a random-effects meta-analysis C-statistic of 0.88 (0.82-0.93) for incident TB. In 
decision curve analysis, the model demonstrated clinical utility for targeting preventative treatment, 
compared to treating all, or no, people with LTBI. We challenge the crude current approach to TB risk 
estimation among people with LTBI, in favour of our evidence-based and patient-centered method, in 




Tuberculosis (TB) accounts for the greatest number of deaths from a single pathogen globally, with an 
estimated 1.5 million deaths and 10 million incident cases in 20181. The World Health Organization 
(WHO) End TB strategy ambitiously aims for a 95% reduction in TB mortality and 90% reduction in TB 
incidence by 20352. As part of this strategy, the priority for low transmission settings is to achieve 
pre-elimination (annual incidence of <1/100,000) by 20352. Preventative antimicrobial treatment for 
latent tuberculosis infection (LTBI) is considered critical for achieving this objective2,3. In the absence 
of an assay to detect viable Mycobacterium tuberculosis (M.tuberculosis) bacteria, LTBI is currently 
clinically defined as evidence of T cell memory to M.tuberculosis, in the absence of concurrent 
disease and any prior treatment4,5. Individuals with LTBI are generally considered to have a lifetime 
TB risk ranging from 5-10%4, which is reduced by 65-80% with preventative treatment6.  
The positive predictive value (PPV) for TB using the current definition of LTBI is <5% over a two year 
period among risk groups such as adult TB contacts7–9. This may lead to a large burden of 
unnecessary preventative treatment, with associated risks of drug toxicity to patients, and excess 
economic costs to health services. The low PPV may also undermine the cascade of care, including 
uptake of preventative treatment among target groups, who perceive their individual risk of developing 
TB to be low10,11. In fact, the risk of TB among individuals with LTBI is highly variable between study 
populations, with incidence rates ranging from 0.3-84.5 per 1,000 person-years of follow-up7,12. Thus, 
quoting the 5-10% lifetime estimate is likely to be inaccurate for many people. Improved risk 
stratification is therefore essential to enable precise delivery of preventative treatment to those most 
likely to benefit5,13. Multiple studies have shown that the magnitude of the T cell response to 
M.tuberculosis is associated with incident TB risk, raising hope that quantitative tuberculin skin test 
(TST) or interferon gamma release assay (IGRA) results may improve predictive ability14,15. However, 
implementing higher diagnostic thresholds alone does not improve prediction on a population level 
due to a marked loss of sensitivity with this approach16.  
In this study, we first sought to characterise the population risk of TB among people tested for LTBI 
using an individual participant data meta-analysis (IPD-MA). In order to study progression from LTBI 
to TB disease more accurately, we focused on settings with low transmission (defined as annual 
incidence ≤20/100,000 persons), where there is a minimal risk of reinfection during follow-up. We 
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confirmed highly variable estimates of risk, necessitating an individual level approach to risk 
estimation. Here we develop and validate a directly data-driven personalized risk predictor for incident 
TB (PERISKOPE-TB) that combines a quantitative T cell response measure with key clinical 





Our systematic review identified 26 studies that aimed to assess the risk of progression to TB disease 
among individuals tested for LTBI in low TB transmission settings; corresponding authors of these 
studies were invited to contribute individual level data (Extended Data Figure 1). Of these, we 
received 18 individual level datasets, including participants recruited in 20 countries. The pooled 
dataset included a total of 82,360 individual records, of whom 51,697 had evidence of LTBI and 826 
were diagnosed with TB. Of the received data, 80,468 participants (including 803 TB cases) had 
sufficient data for inclusion in the primary analysis (Extended Data Figure 2). The characteristics of 
the included study datasets are summarised in Table 1 and Supplementary Table 1. Characteristics of 
the eight eligible studies for which IPD were not obtained were similar to those included in the 
analysis (Supplementary Table 2). Eight studies recruited adults only; the remainder recruited both 
adults and children. The target population was recent TB contacts in nine studies17–25, people living 
with HIV in two studies26,27, mixed immunocompromised groups in two studies28,29, transplant 
recipients in one study30, mixed population screening in two studies31,32, recent migrants in one 
study33, and a combination of recent contacts and migrants in one study9. Median follow-up of all 
participants was 3.7 years (interquartile range (IQR) 2.1-5.3). All contributing studies reported 
baseline assessments for prevalent TB through routine clinical evaluations, and all included culture-
confirmed and clinically diagnosed TB cases in their case definitions. Four studies had a proportion of 
participants lost to follow up >5%18,24,27,28; baseline characteristics of those lost to follow-up were 
similar to those followed-up in each of these studies (Supplementary Table 3). All contributing studies 
achieved quality assessment scores of 6 or 7/7 (Supplementary Table 4).  
Population-level analysis 
In the pooled dataset, the 2-year cumulative risk of incident TB was estimated as 4.0% (2.6-6.3) 
among people with LTBI who did not receive preventative therapy, 0.7% (0.4-1.3) in people with LTBI 
who commenced preventative therapy and 0.2% (0.1-0.4) in people without LTBI (Figure 1; 
Supplementary Table 5). The corresponding 5-year risk of incident TB among these groups was 5.4% 
(3.5-8.5), 1.1% (0.6-2.0) and 0.3% (0.2-0.5), respectively.  
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Among untreated people with LTBI, 2-year risk of incident TB was 14.6% (7.5-27.4) among recent 
child (<15 years) contacts, 3.7% (2.3-6) among adult contacts, 4.1% (1.3-12) among migrants, and 
2.4% (0.8-6.8) among people screened due to immunocompromise (without an index exposure). 
Corresponding 5-year risk was 15.6% (8.0-29.2) among recent child contacts, 4.8% (3.0-7.7) among 
adult contacts, 5.0% (1.6-14.5) among migrants, and 4.8% (1.5-14.3) among people screened due to 
immunocompromise. Among recent child contacts, risk was markedly higher among those aged <5 
years, compared to those aged 5-14 years (2-year risk 26.0% (9.4-60.1) vs. 12.4% (5.7-25.6); Figure 
1).  
Among child contacts, 85.4% and 93.7% of cumulative risk was accrued in the first one and two years 
of follow-up, respectively. Among adult contacts and migrants, the annual risk also declined markedly 
with time. Of the cumulative 5-year risk, 58.0% and 77.5% was accrued in the first one and two years 
of follow-up for adult contacts, with corresponding values among migrants of 66.4% and 81.6%. There 
was a more even distribution of risk during follow-up in the immunocompromised group.  
TB incidence rates in years 0-2 and 2-5 of follow-up, stratified by LTBI result, commencement of 
preventative treatment and indication for screening, are shown in Extended Data Figures 4 and 5. 
Within each of the risk groups assessed, incidence rates among untreated people with LTBI were 
markedly higher in the 0-2 year interval, compared to the 2-5 year interval, but were highly 
heterogeneous across studies (I2 statistics, representing the proportion of variance that is considered 
due to between-study heterogeneity, ranged from 54-91% for incidence rates during the 0-2 year 
interval among untreated people with LTBI, when stratified by indication for screening; forest plots 
shown in Extended Data Figure 5). These findings suggest highly variable TB risk among people with 
LTBI, even within risk groups. 
Prediction model development 
The observed heterogeneity in TB incidence rates across studies, even after stratification by binary 
LTBI result, commencement of preventative treatment and indication for screening, suggests that an 
individual level approach to risk stratification is required. We therefore developed a personalized risk 
prediction model using a subset of the received data (where sufficient individual level variables were 
available) including 528 TB patients among 31,721 participants from 15 studies (Extended Data 
Figure 2). All of these datasets were used for model development and validation, using the internal-
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external cross-validation framework34, described below. Characteristics of the studies included in 
prediction model development and validation were similar to those that were not (Table 1). Our 
modelling approach used a flexible parametric survival model with two degrees of freedom on a 
proportional hazards scale, since this showed the best fit in each imputed dataset. From our list of a 
priori variables of interest, we evaluated nine candidate predictors, of which only previous BCG and 
gender were omitted from the final model. The final prediction model included: age, a composite ‘TB 
exposure’ variable (modelled with time-varying covariates to account for non-proportional hazards), 
time since migration for migrants from countries with high TB incidence, HIV status, solid organ or 
haematological transplant receipt, normalised LTBI test result and preventative treatment 
commencement. The final model coefficients and standard errors, pooled across multiply imputed 
datasets, are summarised in Supplementary Table 6, with visual representations of associations 
between each variable and incident TB risk shown in Figure 2.  
Internal-external cross-validation 
Next, we used the internal-external cross-validation (IECV) framework, iteratively discarding one 
study dataset from the model training set and using this for external validation, to concurrently 
validate the prediction model, explore between-study heterogeneity, and examine generalizability34. 
Model discrimination and calibration parameters for 2-year risk of incident TB from the primary 
validation studies are shown in Figure 3. We assessed discrimination using the C-statistic, which 
ranged from 0.78 (0.47-1.0) in a study of immunocompromised participants with a small number of 
incident TB cases29 to 0.97 (0.94-0.99) in a study of TB contacts18. The random-effects meta-analysis 
estimate of the C-statistic was 0.88 (0.82-0.93).  
Calibration assesses agreement between predicted and observed risk. We assessed calibration 
visually using grouped calibration plots, supplemented by the calibration-in-the-large (CITL) and slope 
statistics (Figure 3). Visual calibration plots suggested reasonable calibration in most studies 
(Extended Data Figure 6). Since incident TB is an infrequent outcome, predictions were appropriately 
low, with average predicted risk <10% in all quintiles of risk. CITL and calibration slopes of 0 and 1 
indicate perfect calibration, respectively. The pooled random-effects meta-analysis CITL estimate was 
0.14 (-0.24-0.53), with evidence of systematic under-estimation of risk in one study (CITL 1.02 (0.61-
1.43)), and over-estimation in one study (CITL -0.64 (-1.09—0.19)). The pooled random-effects meta-
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analysis calibration slope estimate was 1.11 (0.83-1.38). Slopes appeared heterogeneous, though 
visual assessment of calibration plots suggested that these were prone to being extreme due to the 
skewed distribution of predicted and observed risk, likely reflecting the relatively rare occurrence of 
incident TB events.  
Distribution of predicted risk and individual predictions 
Figure 4 shows the distributions of predicted TB risk among participants who did not commence 
preventative treatment from the pooled IECV validation sets, stratified by: (a) binary LTBI test result; 
and (b) indication for screening (among those with a positive test). The median predicted 2-year TB 
risk was 2.0% (interquartile range 0.8-3.7) and 0.2% (0.1-0.3) among participants with positive and 
negative binary LTBI test results, respectively. We then examined incident TB risk in four quartiles of 
predicted risk among untreated participants with positive LTBI tests from the pooled validation sets. 
Kaplan-Meier plots of the four quartiles showed clear separation of observed risk among these four 
groups (Figure 4c), with illustrative predicted survival curves for one randomly sampled individual 
patient per quartile shown in Figure 4d. 
Decision curve analysis 
Net benefit quantifies the trade-off between correctly identifying true positive patients (progressing to 
incident TB), and incorrectly detecting false-positives, with weighting of each by the threshold 
probability35,36. The threshold probability corresponds to a measure of both the perceived risk/benefit 
ratio of initiating preventative treatment, and the threshold of predicted risk above which treatment is 
recommended. How patients and clinicians weigh the relative costs of drug-related adverse events 
(as a result of inappropriate treatment) against the benefits of preventing a case of TB can be 
subjective. Among untreated participants with LTBI from the pooled validation sets in IECV, net 
benefit for the prediction model was greater than either treating all LTBI patients, or treating none, 
throughout a range of threshold probabilities from 0-20% (reflecting a range of clinician and patient 
preferences) (Figure 5).  
Sensitivity analyses 
We re-examined population-level TB risk without any exclusion of prevalent TB (cases diagnosed <42 
days from testing), resulting in markedly higher cumulative risk for each risk group (Extended Data 
Figure 3). Recalculation of model predictor parameters revealed similar directions and magnitudes of 
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effect to the primary model when using shorter and longer definitions of prevalent TB (baseline risk 
was expectedly higher with shorter definitions) and when excluding participants who received 
preventative treatment (Supplementary Table 7). Model parameters were noted to be more extreme 
when using a complete case approach (for variables other than HIV, which was assumed negative 
when missing). The pooled random-effects meta-analysis C-statistic from IECV when limiting to 
participants who did not receive preventative treatment was 0.89 (0.82-0.93), similar to the primary 
analysis (Extended Data Figure 7a). The pooled random-effects meta-analysis C-statistic including 
only participants with a positive binary LTBI test was 0.77 (0.70-0.83). This finding indicates good 
discrimination even among participants with a conventional diagnosis of LTBI, albeit lower than 
discrimination when also including participants with a negative binary LTBI test - likely due to the high 
negative predictive value of LTBI tests when using standard cut-offs (Extended Data Figure 7b). 
Finally, in order to assess model performance in situations where the quantitative test results are not 
available. we imputed an average quantitative positive or negative LTBI test result (based on the 
medians among the study population), according to the binary result in the validation sets. This 
analysis provided a pooled random-effects meta-analysis C-statistic of 0.86 (0.76-0.93; Extended 
Data Figure 7c), and net benefit appeared higher when using this model than either the strategies of 
treating all patients with evidence of LTBI, or no patients, across the range of threshold probabilities. 
However, the model using a binary test result had a lower C-statistic, and slightly lower net benefit 
across most threshold probabilities, compared to the full model using quantitative test results 




In this study, we examined population-level incident TB risk in a pooled dataset of >80,000 individuals 
tested for LTBI in 20 countries with low M.tuberculosis transmission (annual incidence ≤20/100,000 
persons). We found cumulative 5-year risk of incident TB among people with untreated LTBI 
approaching 16% among child contacts, and approximately 5% among recent adult contacts, 
migrants from high TB burden settings, and immunocompromised individuals. A majority of 
cumulative 5-year risk was accrued during the first year among risk groups with an index exposure, 
supporting previous data suggesting that risk of progressive TB declines markedly with increasing 
time since infection13. However, we noted substantial variation in incidence rates even within these 
risk groups, suggesting that an individual level approach to risk stratification is required. Therefore, we 
developed the first directly data-driven model, to our knowledge, to incorporate the magnitude of the T 
cell response to M.tuberculosis with readily available clinical metadata in order to capture 
heterogeneity within risk groups, and generate personalized risk predictions for incident TB in settings 
aiming towards pre-elimination. Clinical co-variates in the final model included age, recent contact 
(including proximity and infectiousness of the index case), migration from high TB burden countries 
(and time since arrival), HIV status, solid organ or haematological transplant receipt, and 
commencement of preventative treatment. The model was externally validated by quantifying the 
meta-analysis C-statistic for predicting incident disease over 2 years, and by evaluating its calibration, 
using recommended methods37. Most importantly, the model showed clear clinical utility for informing 
the decision to initiate preventative treatment, compared to treating all or no patients with LTBI. 
The personalized predictions from our model will enable more precise delivery of preventative 
treatment to those at highest risk of TB disease, while concurrently reducing toxicity and costs related 
to treatment of people at lower risk. Moreover, the model will allow clinicians and patients to make 
more informed and individualised choices when considering initiation of preventative treatment. The 
model also challenges the fundamental notion of an arbitrary binary test threshold for diagnosis of 
LTBI. By incorporating a quantitative measure of immunosensitization to M.tuberculosis, we facilitate 
a shift from the conventional paradigm of LTBI as a binary diagnosis, towards personalized risk 
stratification for progressive TB. This approach takes advantage of stronger T cell responses being a 
correlate of risk, while guarding against a loss of sensitivity by arbitrarily introducing higher test 
thresholds programmatically16.  
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The results of our analyses are consistent with, and extend existing evidence. Recent analyses report 
similar population-level TB incidence rates among adult contacts12, with markedly higher risk among 
young children38. Moreover, these recent meta-analyses confirm highly heterogeneous population-
level estimates, thus justifying an individual-level approach to risk estimation12,38. Previous models 
developed and validated in Peru, a high transmission setting, have generated individual or household-
level TB risk estimates for TB contacts39–41. Another model, parameterised using aggregate data 
estimates from multiple sources, seeks to estimate TB risk following LTBI testing in all settings42. 
However, there are currently no publicly available validation data to support its use and the model 
omits key predictor variables identified in the current study (including the magnitude of the T cell 
response and infectiousness of index cases)42. 
Strengths of the current study include the size of the dataset, curated through comprehensive 
systematic review in accordance with Preferred Reporting Items for a Systematic Review and Meta-
analysis of Individual Participant Data standards43, and with IPD obtained for 18/26 (69%) eligible 
studies. This allowed us to examine progression from LTBI to TB disease using the largest adult and 
pediatric dataset available to date, to our knowledge. We conducted population-level analyses using 
both 1- and 2-stage IPD-MA approaches in order to present both cumulative TB risk and time-
stratified incidence rates, respectively, with consistent results from both. We adhered to transparent 
reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD)44 
standards, using the recommended approach of IECV37, leading to a fully data-driven and validated 
model for personalized risk estimates following LTBI testing. The coefficients presented in the model 
are clinically plausible and have been made publicly available to facilitate further independent external 
validation. Moreover, the contributing datasets included heterogeneous populations of adults, 
children, recent TB contacts, migrants from high TB burden countries, and immunocompromised 
groups from 20 countries across Europe, North America, Asia and Oceania, thus making our results 
generalizable to settings aiming towards pre-elimination globally.  
We also used a comprehensive approach to addressing missing data by using multi-level multiple 
imputation in the primary analysis, assuming missingness at random and in keeping with recent 
guidance34,45. This approach facilitated imputation of variables that were systematically missing from 
some included studies. Previous BCG vaccination and HIV status were noted to be missing from a 
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large proportion of participants. This missingness may have reduced our power to detect an 
association between these variables and incident TB, and BCG vaccination was notably not included 
in the final prognostic model. While increasing data support a role for BCG vaccination in reducing 
sensitisation to M. tuberculosis46,47, additional data are required to further assess the association 
between BCG vaccination and incident TB risk, after adjustment for other co-variates including 
quantitative T cell responses. We supported our primary multiple imputation approach using a 
complete case sensitivity analysis (for variables other than HIV, which was assumed negative when 
missing). This sensitivity analysis revealed similar findings to the primary analyses, though effect 
estimates were noted to be more extreme in the complete case approach, likely owing to a degree of 
bias in the latter, since complete cases analysis assumes no association between the pattern of 
missingness and the outcome (i.e. incident TB) after adjusting for all other covariates48. Given that TB 
incidence and predictor missingness both varied according to contributing study, this assumption is 
unlikely to be valid in the current context.  
We also used a range of arbitrary definitions of prevalent TB in the primary and sensitivity analyses, 
since the aim of our prognostic model is to assess the risk of incident TB, after prevalent TB has been 
clinically ruled out, in order to inform risk/benefit decisions regarding preventative treatment initiation. 
With increasing recognition of the continuum of M.tuberculosis infection using novel diagnostics 
(including incipient and/or subclinical phases)49, the distinction between prevalent and incident 
disease is becoming increasingly blurred. Future studies could consider integration of our prognostic 
model with next generation biomarkers, such as blood transcriptional signatures for incipient TB50,51. 
A limitation of the study is that its generalisability is restricted to low transmission settings (annual 
incidence ≤20/100,000 persons). The rationale for limiting to such settings was, firstly, to examine 
progression from LTBI to TB disease more accurately, by reducing risk of re-infection with 
M.tuberculosis during follow-up. Secondly, the majority of the population in high transmission settings 
are likely to have a positive LTBI test result, further undermining test specificity for progression to TB 
disease52. Since the quantitative LTBI test result is a strong predictor in our model, a different 
prediction model may therefore be required in such settings. For example, a recent study developing 
a prediction model for TB among close contacts in Peru found that the TST result added no value to 
the model39. Future studies could test our model for use in high transmission settings, updating the 
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parameters as necessary, in order to extend its application to these settings. A second limitation of 
the current study is that model calibration was observed to be imperfect during external validation. 
However, conventional metrics (such as the calibration slope) may not be entirely appropriate in this 
context, which has a highly skewed distribution of predicted and observed risk, reflecting the rare 
occurrence of incident TB events. Reassuringly, in decision curve analysis, which accounts for both 
discrimination and calibration performance in quantifying net benefit, the model showed clinical 
utility35. Future studies may evaluate the full health economic impact of programmatic implementation 
of the model.  
A further limitation is that, due to a lack of data from contributing studies, other potential predictors 
that may be associated with incident TB risk (including diabetes, malnutrition, fibrotic chest x-ray 
lesions and other immunosuppression)4 were not evaluated. These unmeasured covariates may have 
contributed to imperfect discrimination and calibration, along with residual heterogeneity in model 
performance between datasets. As additional studies are published, the prognostic model can be 
prospectively evaluated and updated as required. We also note that offer and acceptance of 
preventative treatment may be more likely among people at higher risk of TB. We therefore accounted 
for preventative treatment provision in the model by including it as a co-variate along with our other 
predictors of interest, as widely recommended53. However, residual confounding by indication cannot 
be excluded in observational studies. In addition, the present model is not applicable for patients 
commencing biologic agents since no datasets were identified that examined the natural history of 
LTBI in the context of biologic therapy, in the absence of preventative treatment for TB. A ‘hybrid’ 
modelling approach, with mathematical parameterisation of relative risk for any given biologic agent, 
may be required to extend its application to these therapies. Since the quantitative LTBI test result is 
a strong predictor in our model, predictions may also be attenuated in the context of advanced 
immunosuppression7. Reassuringly. performance appeared adequate in a dataset of 
immunocompromised individuals during validation29.  
In summary, we present a freely available and directly data-driven personalized risk predictor for 
incident TB (PERISKOPE-TB; periskope.org). This tool will allow a programmatic paradigm shift for 
TB prevention services in settings aiming towards pre-elimination globally, by facilitating shared 
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Figure 1: Population-level cumulative risk of incident tuberculosis during follow-up. 
Risk is stratified by binary latent TB test result, provision of preventative treatment, and indication for 
screening among participants with untreated latent infection (total n=80,468 participants). Cumulative 
risk is estimated using flexible parametric survival models with random effects intercepts by source 
study, separately fitted to each risk group. Prevalent TB cases (diagnosed within 42 days of 
recruitment) are excluded. Each plot is presented as point estimates (solid line) and 95% confidence 
intervals (shaded area). PT = preventative treatment. Numbers of participants, TB cases and numeric 
cumulative risk estimates for each plot are presented in Supplementary Table 5. Cumulative TB risk 
including prevalent TB cases is presented in Extended Data Figure 3. 
Figure 2: Visual representations of associations between predictors and incident tuberculosis.  
Illustrative estimates are shown for a 33-year old migrant from a high TB burden setting. The example 
‘base case’ patient does not commence preventative treatment, is not living with HIV, has not 
received a previous transplant, and has an ‘average’ positive latent TB test. We vary one of these 
predictors in each plot ((a) age; (b) normalised latent TB test result; (c) years since migration; (d) 
exposure to M. tuberculosis; (e) HIV status; (f) transplant receipt; and (g) preventative treatment). 
Each plot is presented as point estimates (solid line) and 95% confidence intervals (shaded area). 
The model was trained on a pooled dataset (n=31,090 participants). Model parameters are provided 
in Supplementary Table 6. ‘Household smear+ contact’ = household contact of sputum smear-positive 
index case; ‘Other contact’ = contact of non-household or smear-negative index case; ‘Migrant’ = 
migrant from high TB incidence country, without recent contact. 
Figure 3: Forest plots showing model discrimination and calibration metrics for predicting 2-
year risk of incident tuberculosis.  
Discrimination is presented as the C-statistic; calibration is presented as calibration-in-the-large 
(CITL) and the calibration slope. Data from nine primary validation studies are shown,from internal-
external cross-validation of the model (developed among n=31,090 participants; validated among 
25,504 in this analysis). ‘TB’ column indicates number of incident TB cases within 2 years of study 
entry and ‘N’ indicates total participants per study included in analysis. Each forest plot shows point 
estimates (squares) and 95% confidence intervals (error bars). Pooled estimates are shown as 
diamonds. Calibration slopes >1 suggest under-fitting (predictions are not varied enough), while 
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slopes <1 indicate over-fitting (predictions are too extreme). Calibration-in-the-large indicates whether 
predictions are systematically too low (CITL >0) or too high (CITL <0). Dashed lines indicate line of no 
discrimination (C-statistic), and perfect calibration (CITL and slope), respectively.  
Figure 4: Distribution of predictions and risk of incident tuberculosis in four quartiles of risk 
for people with positive latent TB tests.  
Distribution of risk from prediction model using pooled validation sets of people not receiving 
preventative therapy from internal-external cross-validation of the model (n=27,511 participants), 
stratified by (a) binary latent TB test result and (b) indication for screening among untreated people 
with positive LTBI tests. (c) Kaplan-Meier plots for quartile risk groups (1=lowest risk) of untreated 
individuals with positive LTBI tests (n=6,418 participants). Quartiles represent four equally sized 
groups based on predicted risk of incident TB, from the pooled validation sets derived from internal-
external cross-validation of the prediction model. P value represents Log-rank test (p=1.137 x 10-40). 
(d) Randomly sampled individual patients from each risk quartile. Patient 1 is a 22-year-old with no TB 
exposure and a normalised latent TB test result on the 68th percentile; Patient 2 is a 41-year-old 
migrant from a high TB burden country (3.8 years since migration) with normalised latent TB test 
result on the 80th percentile; Patient 3 is a 51-year-old household contact of a smear positive index TB 
case with a normalised latent TB test result on the 79th percentile; Patient 4 is a 33-year-old 
household contact of a smear positive index TB case with a normalised latent TB test result on the 
94th percentile. All four example patients are HIV negative and are not transplant recipients. 
Equivalent values of normalised percentile test results for QuantiFERON, T-SPOT.TB and tuberculin 
skin test are shown in Supplementary Table 10. Plots (c) and (d) are presented as point estimates 
(solid line) and 95% confidence intervals (shaded area). 
Figure 5: Decision curve analysis. 
Shown as net benefit of the prediction model among untreated participants from the pooled validation 
sets with positive binary latent TB tests (n=6,418 participants), compared to ‘treat all’ and ‘treat none’ 
strategies across a range of threshold probabilities (x-axis). Net benefit quantifies the trade-off 
between correctly identifying true positive progressors to incident TB, and incorrectly detecting false-
positives, with weighting of each by the threshold probability35. The threshold probability corresponds 
to a measure of both the perceived risk/benefit ratio of initiating preventative treatment, and the 
percentage cut-off for the prediction model, above which treatment is recommended. Net benefit 
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appeared higher than either the strategies of treating all patients with evidence of LTBI, or no patients, 
throughout the range of threshold probabilities, suggesting clinical utility. For illustration, a patient who 
is very concerned about developing TB disease, but not concerned regarding side-effects of 
preventative treatment, may have a low threshold probability (e.g. 1%, which is equivalent to a 
risk:benefit ratio of 1:99, i.e. the outcome of developing TB is considered to be 99 times worse than 
taking unnecessary preventative treatment). In contrast, a patient who is less concerned about 
developing TB but is very concerned about side-effects of preventative treatment may have a higher 
threshold probability (e.g. 10% which is equivalent to a risk:benefit ratio of 1:9). The unit of net benefit 
is ‘true positives’35. For instance, a net benefit of 0.01 would be equivalent to a strategy where 1 
patient per 100 tested was appropriately given preventative treatment, as they would otherwise have 




Table 1: Characteristics of contributing studies included in individual participant data meta-analysis. 
Additional study characteristics are shown in Supplementary Table 1. IQR = interquartile range. 
Authors Publication 
Year 










Abubakar et al9 2018 UK 10,045 Adults Contacts & migrants 4.7 (3.7-5.5) 147 10 (0.1%) Yes 7/7
Aichelburg et al26 2009 Austria 830 Adults People with HIV 1.2 (0.7-1.4) 11 25 (3%) Yes 7/7
Altet et al17 2015 Spain 1,339 Adults & children Contacts 4 (4-4) 95 0 (0%) Yes 7/7
Diel et al18 2011 Germany 1,414 Adults & children Contacts 3.5 (2.5-4.2) 19 381 (26.9%) Yes 7/7
Dobler & Marks19 2013 Australia 12,212 Adults & children Contacts 4.2 (2-6.9) 94 351 (2.9%) No* 7/7
Doyle et al27 2014 Australia 919 Adults People with HIV 2.9 (1.7-3.6) 2 47 (5.1%) Yes 7/7
Erkens et al32 2016 Netherlands 14,241 Adults & children Mixed population screening 5.5 (3-7.4) 134 NA No* 6/6
Geis et al20 2013 Germany 1,283 Adults & children Contacts 0.8 (0.4-1.1) 33 62 (4.8%) Yes 6/6
Gupta et al25 2020 UK 623 Adults Contacts 1.9 (1.6-2.2) 13 0 (0%) Yes 7/7
Haldar et al21 2013 UK 1,411 Adults & children Contacts 1.9 (1.3-2.4) 37 30 (2.1%) Yes 7/7
Lange et al28 2012 Germany 456 Adults Immunocompromised 2.8 (2-3.1) 1 42 (9.2%) Yes 7/7
Munoz et al30 2015 Spain 76 Adults Transplant recipients 4.3 (3.6-4.8) 2 0 (0%) Yes 7/7
Roth et al31 2017 Canada 22,949 Adults & children Mixed population screening 3 (1.8-4.3) 58 NA Subset* 6/6
Sester et al29 2014 Multiple European countries 1,464 Adults Immunocompromised 2.7 (1.5-3.5) 11 7 (0.5%) Yes 7/7
Sloot et al22 2014 Netherlands 5,895 Adults & children Contacts 5.9 (3.6-7.7) 81 NA Yes 7/7
Yoshiyama et al23 2015 Japan 625 Adults & children Contacts 1.8 (1.4-2) 12 0 (0%) Yes 6/7
Zellweger et al24 2015 Multiple European countries 5,237 Adults & children Contacts 2.6 (1.9-3.5) 55 1339 (25.6%) Yes 7/7
Zenner et al33 2017 UK 1,341 Adults Migrants 3.7 (3-4.8) 21 NA No* 7/7
Total   82,360 3.7 (2.1-5.3) 826 2294 (2.8%) 
*Not included in prediction modelling due to lack of data on proximity or infectiousness of index cases19, or absent quantitative LTBI test data32,33. A subset of 
the dataset was included in the prediction model for the Roth et al study31; contacts and migrants were excluded due to no data being available on country of 
birth or infectiousness of index cases, respectively.  




Systematic review and pooling of individual participant data 
We conducted a systematic review and IPD-MA, in accordance with Preferred Reporting Items for a 
Systematic Review and Meta-analysis of Individual Participant Data standards43, to investigate the 
risk of progression to TB disease among people tested for LTBI in low transmission settings. The 
study is registered with PROSPERO (CRD42018115357). We searched Medline and Embase for 
studies published 01/01/2002 – 31/12/2018 using comprehensive MeSH and keyword terms for ‘TB’, 
‘IGRA’, ‘TST’, ‘latent TB’, and ‘predictive value’, without language restrictions. Longitudinal studies 
that primarily aimed to assess the risk of progression to TB disease among individuals tested for LTBI 
and that were conducted in a low TB transmission setting (defined as annual incidence ≤20/100,000 
persons at the midpoint of the study) were eligible for inclusion. The full search strategy and eligibility 
criteria are provided in Supplementary Tables 8 and 9. Titles and abstracts underwent a first screen; 
relevant articles were selected for the second screen, which included full text review. Both first and 
second screens were performed by two independent reviewers, with disagreements resolved through 
discussion and arbitration by a third reviewer where required. Corresponding authors of eligible 
studies were invited to contribute IPD. Received data were mapped to a master variables list, and the 
integrity of the IPD were examined by comparing original reported results with re-analysed results 
using contributed data. Quality assessment was performed using a modified version of the Newcastle-
Ottawa scale for cohort studies54. 
Definitions 
Participants entered the cohort on the day of LTBI screening or diagnosis, and exited on the earliest 
of censor date (last date of follow-up), active TB diagnosis date, date of death, or date of loss to 
follow-up (where available). LTBI was defined as any positive LTBI test (TST or commercial IGRA), 
using TST thresholds as defined by the contributing study (a 10mm cut-off was used for studies that 
assessed multiple thresholds). Quantitative IGRA thresholds were calculated according to standard 
manufacturer guidelines. IGRAs included three generations of QuantiFERON TB assays 
(QuantiFERON Gold-In-Tube, QuantiFERON Gold, QuantiFERON-TB Gold Plus; Qiagen, Hilden, 
Germany), which were assumed to be equivalent25, and T-SPOT.TB (Oxford Immunotec, UK). 
Microbiologically confirmed and/or clinically diagnosed TB cases were included, as per contributing 
study definitions. In the absence of a widely accepted temporal distinction between prevalent and 
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incident disease, prevalent TB at the time of screening was arbitrarily defined as a TB diagnosis 
within 42 days of enrolment; these cases were omitted from the primary analysis. Alternative shorter 
and longer temporal definitions were tested as sensitivity analyses. Participants with missing 
outcomes or durations of follow-up were considered lost to follow-up. ‘Preventative treatment’ was 
defined as any LTBI treatment regimen recommended by the WHO52. All contributing studies included 




In a one-stage IPD-MA approach, we used flexible parametric survival models, with a random effect 
intercept by source study to account for between study heterogeneity, to examine population level risk 
of incident TB, stratified by LTBI screening result (positive vs negative) and provision of LTBI 
treatment (commenced vs. not commenced). We further examined progression risk among untreated 
participants with LTBI, stratified by indication for screening (recent child contacts (<15 years) vs adult 
contacts vs migrants vs immunocompromised), by separately fitting random-effect flexible parametric 
survival models to each risk group. Child contacts were further stratified by age (<5 vs. 5 to 14 years). 
Incidence rates 
We also calculated TB incidence rates (per 1,000 person-years) in a two-stage IPD-MA approach, 
stratified by LTBI screening result, provision of LTBI treatment, and indication for screening. Rates 
were calculated separately for the 0-2 year and 2-5 year follow-up intervals. Pooled incidence rate 
estimates for each risk group and follow-up interval were derived using random intercept Poisson 
regression models, without continuity correction for studies with zero events, in the meta package in 
R56.  
Prediction model analysis 
Variables of interest 
We then developed and validated a personalized prediction model for incident TB, in accordance with 
transparent reporting of a multivariable prediction model for individual prognosis or diagnosis 
(TRIPOD) guidance44. For this analysis, we included studies that reported quantitative LTBI test 
results, proximity and infectiousness (based on sputum smear status) of index cases for contacts, and 
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country of birth and time since entry for migrants, since we considered these variables fundamental a 
priori.  Using this subset of the data, we examined the availability of a range of variables of interest, 
specified a priori, in the contributing datasets to determine eligibility for inclusion as candidate 
predictors in the model. We determined that the following predictors were available from a sufficient 
number of datasets for further evaluation: age, gender, quantitative LTBI test result, previous BCG 
vaccination, recent contact (including proximity and infectiousness of index case), migration from a 
high TB incidence setting, time since migration, solid organ or haematological transplant receipt, HIV 
status and TB preventative treatment commencement.  
Variable transformations 
Previous data have shown that quantitative TST, QuantiFERON Gold-in-tube (QFT-GIT) and T-
SPOT.TB results are associated with risk of incident TB16. However, each LTBI test is reported using 
different scales, and it has hitherto been unclear whether quantitative values of each test are 
equivalent with respect to incident TB risk. To assess this further, we examined a sub-population of 
the entire cohort where all three tests were performed among the same participants in head-to-head 
studies. We normalised quantitative results for the TST, QFT-GIT and T-SPOT.TB to a percentile 
scale using this head-to-head population, and examined the association between normalised result 
and risk of incident TB using Cox proportional hazards models with restricted cubic splines. Since 
TST cut-offs are frequently stratified by BCG vaccination and HIV status57,58, we also examined 
whether these variables modified the association between quantitative TST measurement and 
incident TB risk in the head-to-head subpopulation. Since there was no evidence that including 
interaction terms for either BCG or HIV improved model fit (based on Akaike Information Criteria 
(AIC)), we used unadjusted TST measurements. This analysis revealed that the normalised percentile 
results for each test (unadjusted TST, QFT-GIT and T-SPOT.TB) appeared to be associated with 
similar risk of incident TB (Extended Data Figure 8). The LTBI tests implemented differed between 
contributing studies. From this point, all LTBI test results were therefore normalised to this percentile 
scale to enable data harmonisation across studies, by transforming raw quantitative results to the 
relevant percentile using look-up tables derived from the head-to-head population (Supplementary 
Table 10). Since most people evaluated for LTBI under routine programmatic conditions have a single 
test performed, we only included one test result per participant in the prediction model. We 
preferentially included tests where quantitative results were available. Where quantitative results were 
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available for more than one test, we preferentially included the QuantiFERON result (since this was 
the most commonly used test in the dataset), followed by T-SPOT.TB, and then the TST.  
Recent contacts were categorised as either ‘smear positive and household’ or ‘other’ contacts, since 
there was no evidence of separation of risk among additional subgroups of the ‘other’ contacts 
stratum during exploratory univariable analyses (Extended Data Figure 8). Since we considered 
migration from a high TB burden country (defined as annual TB incidence ≥100/100,000 persons at 
the year of migration) to be a proxy for prior TB exposure, we included this in a composite ‘TB 
exposure’ variable, which included four mutually-exclusive levels: household contact of smear-positive 
index case; ‘other’ contact; migrant from country with high TB incidence, without recent contact; and 
no exposure. There was no evidence of separation of incident TB risk when stratified by TB incidence 
in country of birth above the binary country of birth threshold (TB incidence ≥100/100,000 persons) 
among migrants, or when stratified by country of birth among recent contacts (Extended Data Figure 
8).  
Age and normalised test result variables were modelled using restricted cubic splines (using a default 
of 5 knots placed at recommended intervals59) to account for their non-linear associations with 
incident TB.  
Multiple imputation 
A data dictionary and summary of missingness of candidate predictor variables is provided in 
Supplementary Table 11. We performed multi-level multiple imputation to account for sporadically and 
systematically missing data (assuming missingness at random48), while respecting clustering by 
source study, in accordance with recent guidance45 using the micemd package in R60. We used 
predictive mean matching for continuous variables, due to their skewed distributions. We included all 
variables (including transformations) assessed in the downstream prediction model in the imputation 
model, along with auxiliary variables, to ensure congeniality. Multi-level imputation was done 
separately for contacts and non-contacts due to expected heterogeneity between these groups. We 
generated ten multiply imputed datasets, with 25 between-imputation iterations. Model convergence 
was assessed by visually examining plots of imputed parameters against iteration number. All 
downstream analyses were done in each of the ten imputed datasets; model coefficients and 
standard errors were combined using Rubin’s rules61.  No imputation was done for participants 
31 
 
missing binary LTBI test results, or for those lost to follow-up; these individuals were excluded. For 
recent TB contacts or people screened due to HIV infection with missing data on transplant status, 
this was assumed negative due to the very low prevalence of transplant receipt when observed 
among these risk groups (<0.5%). 
Variable selection and final model development 
We performed backward selection of the nine candidate predictors in each of the pooled imputed 
datasets, using AIC. Variables that were selected in more than 50% of the imputed datasets were 
included in the final model. T cell responses to M.tuberculosis may be impaired in the context of 
immunosuppression (including among people with HIV or transplant recipients)7. We therefore also 
tested whether there was a significant interaction between HIV or transplant and the normalized 
percentile test result variable, in order to assess whether the association between the quantitative test 
result and incident TB risk varied according to HIV or transplant status. This analysis showed no 
evidence of effect modification, based on AIC, thus these interaction terms were not included in the 
final model.  
We used flexible parametric survival models in order to facilitate estimation of baseline risk throughout 
the duration of follow-up62, using the rstpm2 package63. We examined a range of degrees of freedom 
for the baseline hazard, using proportional hazards and odds scales, and selected the final model 
parameters based on the lowest AIC across the imputed datasets. Visual inspection of survival curves 
suggested non-proportional hazards for the composite exposure category; we therefore assessed 
whether including this variable as a time-varying covariate (by including an interaction between the 
composite exposure covariate of interest and time) improved model fit64. Since the AIC for the time-
varying covariate model was lower across all imputed datasets, this time-varying covariate approach 
was used for the final model.  
Internal-external cross-validation 
Following development of the final model, we used the internal-external cross-validation (IECV) 
framework for model validation, allowing concurrent assessment of  between-study heterogeneity and 
generalisability34. In this process, one entire contributing study dataset is iteratively discarded from the 
model training set and used for external validation. This process is repeated until each dataset has 
been used once for validation. The primary outcome for validation was 2-year risk of incident TB. We 
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included datasets with a minimum of 5 incident TB cases, and where participants had been included 
regardless of LTBI test result, as the primary validation sets. We assessed model discrimination using 
the C-statistic for 2-year TB risk. Model calibration was assessed by visually examining calibration 
plots of predicted risk vs. Kaplan Meier estimated observed 2-year risk in quintiles, and using the 
calibration slope and calibration-in-the-large (CITL) statistics65. Calibration slopes >1 suggest under-
fitting (predictions are not varied enough), while slopes <1 indicate over-fitting (predictions are too 
extreme). Slopes were calculated by fitting survival models with the model linear predictor as the sole 
predictor; the calculated coefficient for the linear predictor provides the calibration slope. CITL 
indicates whether predictions are systematically too low (CITL >0) or too high (CITL <0). We 
calculated CITL for each validation set by fixing all model coefficients from model development 
(including the baseline hazard terms), and re-estimating the intercept. The difference between the 
development model and recalculated validation model intercepts provided the CITL statistic66.  
Pooling of IECV parameters and random-effects meta-analysis 
IECV was performed on each imputed dataset. Validation set C-statistics, calibration slopes and CITL 
metrics were pooled for each study across imputations using Rubin’s rules61. We then meta-analysed 
these metrics across validation studies with random-effects, using logit-transformed C-statistics as 
previously recommended67, to derive pooled discrimination and calibration estimates. The IECV 
validation sets were also pooled, with averaging of the predicted 2-year risk of TB for each individual 
in the validation sets across imputations, for downstream decision curve analyses as described 
below. 
Decision curve analysis 
Decision curve analysis complements model validation parameters by assessing the potential clinical 
utility of a prediction model35,36. Net benefit quantifies the proportion of true positive cases detected 
minus the proportion of false positives, with weighting of each by the ‘threshold probability’35. The 
‘threshold probability’ reflects both the risk/benefit ratio of initiating preventative treatment, and the 
percentage cut point for the prediction model, above which treatment is recommended. We calculated 
net benefit across a range of clinically relevant threshold probabilities (to account for a range of 
clinician and patient preferences) in comparison to the default strategies of treating either all or no 
patients with a positive LTBI test. We analysed net benefit using the stdca command from the 
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ddsjoberg/dca package in R68, using the stacked validation sets of untreated participants with positive 
LTBI tests from IECV (to ensure that each individual for whom a prediction was generated had not 
been included in the model training set used to derive that prediction).  
Sensitivity analyses 
First, we re-examined population-level TB risk without exclusion of prevalent TB cases. Second, we 
recalculated prediction model parameters using: alternative definitions of prevalent TB (ranging from 
diagnosis within 0 to 180 days of recruitment); a complete case approach (for all variables except for 
HIV status, which was assuming negative where this was missing); and exclusion of participants who 
received preventative treatment. Parameters for each of these models were compared with the 
primary model (without time-varying covariates to facilitate interpretation).  
We also examined IECV discrimination parameters for validation datasets when: (a) restricted to 
participants with positive binary LTBI tests; (b) excluding those who received preventative treatment; 
and (c) imputing an average quantitative positive or negative LTBI test result (based on the medians 
among the study population), according on the binary result. The latter analysis was done to assess 
model performance in situations where the quantitative test result is not available.  
Ethics 
This study involved analyses of fully depersonalized data from previously published cohort studies, 
with data pooling via a safe haven. Ethical approvals for sharing of data were sought and obtained by 
contributors of individual participant data, where required.  
Data availability statement 
The individual participant data pooled for this analysis are subject to data sharing agreements with the 
original study authors. The data may be shared to interested parties by the corresponding authors of 
the original studies, subject to data sharing agreements. 
Code availability 
The final prognostic model developed in this study has been made freely available, to enable 
immediate implementation in clinical practice and independent external validation in new datasets 
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